Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain

BMC Infectious Diseases

Research Article

Jorge Navarro-Pérez¹  Javier Díez-Domingo²  Joan Puig-Barberá²  Ana M Cebrián-Cuenca³  María San-Martín-Rodríguez⁴ 

[1] CIBER Epidemiology and Public Health (CIBERESP), Spain, Calle Poeta Durán y Tortajada 7-55, 46022, Valencia, Spain;Centro Superior de Investigaciones en Salud Pública de Valencia (CSISP), Avenida Cataluña 21, 46020, Valencia, Spain;Centro de Salud de Ayora, Avenida Argentina, Ayora, Valencia, Spain;Departamento Médico Sanofi Pasteur MSD, Paseo de la Castellana 141, Madrid, Spain;

关键词: Herpes Zoster;    Postherpetic Neuralgia;    Primary Care Visit;    Autonomous Community;    Zoster Vaccine;   

DOI  :  10.1186/1471-2334-11-302

 received in 2011-02-15, accepted in 2011-11-01,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundData on the epidemiology and costs related to herpes zoster (HZ) and postherpetic neuralgia (PHN) in Spain are scarce; therefore, studies are needed to evaluate the epidemiological and economic impact of HZ and its most common complication, PHN. The present study aimed to estimate the clinical and economic burden of HZ and PHN in Valencia (Spain).MethodsWe prospectively analyzed the burden of HZ and PHN and their attributable costs in patients from 25 general practices in the Autonomous Community of Valencia serving 36,030 persons aged > 14 years. All patients with a clinical diagnosis of HZ who attended these centers between December 1st 2006 and November 30th 2007 were asked to participate. Patients included were followed for 1 year.ResultsOf the 130 cases of HZ followed up, continued pain was experienced by 47.6% (95% confidence interval (CI) = 35.6-56.7%) at 1 month after rash onset, by 14.5% (95% CI = 7.8-1.2%) at 3 months, by 9.0% (95% CI = 3.7-14.3%) at 6 months, and by 5.9% (95% CI = 1.5-10.3%) at 12 months. The percentage of patients with PHN increased with age, from 21.4% (95% CI = 8.3-40) in patients < 50 years to 59.2% (95% CI = 44.4-74) in patients ≥ 70 years. The estimated total cost for the 130 HZ cases during the follow-up period was €49,160 ($67,349). Mean cost per patient was €378 (range 53-2,830) ($517, range 73-3,877).ConclusionsThis study shows that PHN is a relatively common complication of HZ and that both conditions combined give rise to a significant clinical and economic burden for patients and providers.

【 授权许可】

Unknown   
© Cebrián-Cuenca et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.